Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Launched by EGYMEDICALPEDIA · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called TWEAK for patients with plaque psoriasis, a skin condition that can also come with another disease called psoriatic arthritis. Psoriasis can lead to other health issues like depression and heart problems, and about 40% of people with psoriasis may develop psoriatic arthritis, which causes joint pain and swelling. The goal of this study is to find out if TWEAK can help improve the quality of life for these patients and potentially reduce the risk of developing other diseases.

To participate in this trial, you need to be an adult with plaque psoriasis and have active psoriatic arthritis, meaning you have painful and swollen joints despite trying other treatments. Unfortunately, if you have had certain other treatments or serious infections, or if you are pregnant or breastfeeding, you may not be eligible. The trial is not yet recruiting participants, but if you qualify, you will have the chance to receive the new treatment and be closely monitored by medical professionals throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of both sexes with psoriasis vulgaris and Psoriatic arthritis.
• • Active PsA with three or more tender and swollen joints and met the CASPAR, despite previous treatment with NSAIDs, DMARDs or anti-TNFs
• Exclusion Criteria:
• • Previously received biologic immunomodulating agents, except for those targeting TNF
• • Previously been treated with three or more different TNF inhibitors
• • Active, ongoing inflammatory diseases other than PsA
• • Active TB (patients with latent TB had to commence treatment for latent TB before study entry)
• • A history of hepatitis B or C, human immunodeficiency virus, or any active systemic infection within the 2 weeks before baseline
• • History of ongoing, chronic or recurrent infections, or evidence of active TB infection
• • History of malignancy within the past 5 years (except for basal cell carcinoma or actinic keratosis that has been treated with no evidence of recurrence in the past 3 months, in situ cervical cancer or non-invasive malignant colon polyps that had been removed)
• • Underlying metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious or gastrointestinal conditions which, in the opinion of the investigator, immunocomprimised the patient and/or placed the patient at unacceptable risk for participation
• • Pregnant or nursing (lactating) women and women of child-bearing potential unwilling to use effective contraception during the study and for 16 weeks after stopping treatment